Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinastine Hydrochloride,Azelastine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2024
Lead Product(s) : Epinastine Hydrochloride,Azelastine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2023
Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azelastine Hydrochloride,Mometasone Furoate,Olopatadine Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Azelastine Allergen Chamber - Onset of Action Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : Azelastine Hydrochloride,Mometasone Furoate,Olopatadine Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2023
Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2022
Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azelastine Hydrochloride,Mometasone Furoate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : Azelastine Hydrochloride,Mometasone Furoate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azelastine Hydrochloride,Beclomethasone Dipropionate
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2021
Lead Product(s) : Azelastine Hydrochloride,Beclomethasone Dipropionate
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dymista Allergen Chamber - Onset of Action Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Azelastine Hydrochloride,Fluticasone Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable